- Home
- SOS vs LPTX Comparison
SOS vs LPTX Comparison
Compare SOS & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOS
- LPTX
- Stock Information
- Founded
- SOS 2004
- LPTX 2011
- Country
- SOS China
- LPTX United States
- Employees
- SOS N/A
- LPTX N/A
- Industry
- SOS Finance: Consumer Services
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOS Finance
- LPTX Health Care
- Exchange
- SOS Nasdaq
- LPTX Nasdaq
- Market Cap
- SOS 18.2M
- LPTX 14.7M
- IPO Year
- SOS 2017
- LPTX N/A
- Fundamental
- Price
- SOS $2.47
- LPTX $0.31
- Analyst Decision
- SOS
- LPTX Hold
- Analyst Count
- SOS 0
- LPTX 1
- Target Price
- SOS N/A
- LPTX N/A
- AVG Volume (30 Days)
- SOS 197.6K
- LPTX 336.6K
- Earning Date
- SOS 09-23-2025
- LPTX 08-11-2025
- Dividend Yield
- SOS N/A
- LPTX N/A
- EPS Growth
- SOS N/A
- LPTX N/A
- EPS
- SOS N/A
- LPTX N/A
- Revenue
- SOS $231,424,000.00
- LPTX N/A
- Revenue This Year
- SOS N/A
- LPTX N/A
- Revenue Next Year
- SOS N/A
- LPTX N/A
- P/E Ratio
- SOS N/A
- LPTX N/A
- Revenue Growth
- SOS 150.42
- LPTX N/A
- 52 Week Low
- SOS $2.25
- LPTX $0.22
- 52 Week High
- SOS $15.51
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- SOS 22.67
- LPTX 39.73
- Support Level
- SOS $6.77
- LPTX $0.33
- Resistance Level
- SOS $7.14
- LPTX $0.38
- Average True Range (ATR)
- SOS 0.68
- LPTX 0.03
- MACD
- SOS -0.67
- LPTX -0.00
- Stochastic Oscillator
- SOS 3.28
- LPTX 22.27
About SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.